1. In Vivo
  2. >>Innovation

Real-Time Molecular Sensing Heralds New Era Of Continuous Monitoring

The Case For DNA Aptamer-Based Sensors In Monitoring Vancomycin Concentrations And Creatinine Levels In Real-Time

The traditional method of performing conventional lab diagnostic testing, using blood draws and waiting often long periods for the results, presents challenges for clinicians dealing with complex medical conditions. Continuous diagnostic monitoring based on real-time molecular sensing is the long-awaited solution.   

infinity sign
Continuous Glucose Monitors have demonstrated the power of real-time information in treating patients • Source: Shutterstock

A major drawback of the current process of lab diagnostic testing is that it lacks the ability to factor in trend data and real-time insights that allow for the informed decisions that doctors now more frequently require.

The diagnostics industry has been searching for a single technology capable of continuous diagnostic monitoring (CDM) and real-time monitoring of multiple analytes. The solution has been found by observing natural processes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.